Two Sigma Investments LP Lowers Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Two Sigma Investments LP decreased its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 20.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 166,119 shares of the company's stock after selling 42,120 shares during the period. Two Sigma Investments LP owned 0.21% of Kura Oncology worth $1,447,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Kura Oncology by 14.6% during the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock valued at $41,973,000 after purchasing an additional 615,211 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Kura Oncology during the fourth quarter valued at approximately $38,769,000. Millennium Management LLC increased its stake in shares of Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Kura Oncology by 35.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock valued at $12,419,000 after purchasing an additional 372,196 shares in the last quarter. Finally, Prosight Management LP increased its stake in shares of Kura Oncology by 87.9% during the fourth quarter. Prosight Management LP now owns 1,325,000 shares of the company's stock valued at $11,541,000 after purchasing an additional 619,891 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KURA. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Barclays reduced their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. UBS Group reduced their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, Wall Street Zen downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Stock Performance

KURA stock traded up $0.16 on Friday, hitting $6.73. The company had a trading volume of 765,456 shares, compared to its average volume of 1,216,493. The stock's 50-day simple moving average is $6.07 and its 200 day simple moving average is $7.63. The stock has a market cap of $582.65 million, a price-to-earnings ratio of -2.85 and a beta of 0.40. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. As a group, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.